<em>Pseudomonas aeruginosa</em>: Recent Advances in Vaccine Development

<em>Pseudomonas aeruginosa</em>: Recent Advances in Vaccine Development

<i>Pseudomonas aeruginosa</i> is an important opportunistic human pathogen. Using its arsenal of virulence factors and its intrinsic ability to adapt to new environments, <i>P. aeruginosa</i> causes a range of complicated acute and chronic infections in immunocompromised indi...

Full description

Bibliographic Details
Main Authors:	Matthew Killough, Aoife Maria Rodgers, Rebecca Jo Ingram
Format:	Article
Language:	English
Published:	MDPI AG 2022-07-01
Series:	Vaccines
Subjects:	<i>Pseudomonas aeruginosa</i> vaccines cystic fibrosis antibiotic resistance mucosal immunity
Online Access:	https://www.mdpi.com/2076-393X/10/7/1100

Similar Items

Polymicrobial Interactions in the Cystic Fibrosis Airway Microbiome Impact the Antimicrobial Susceptibility of <i>Pseudomonas aeruginosa</i>
by: Emma Reece, et al.
Published: (2021-07-01)

Detection of Morphotyping Characteristics Identification Antibiotic Resistance of Pseudomonas aeruginosa Isolated from Patients with Cystic Fibrosis
by: Hossein Fazeli, et al.
Published: (2012-03-01)

THE PREVALENCE OF PSEUDOMONAS AERUGINOSA STRAINS IN INFANTS WITH CYSTIC FIBROSIS WITHIN A HOSPITAL IN NORTH EASTER OF ROMANIA
by: Oana Alexandra Ciocan, et al.
Published: (2016-11-01)

Preclinical Development of a Bacteriophage Cocktail for Treating Multidrug Resistant <em>Pseudomonas aeruginosa</em> Infections
by: Sophie Camens, et al.
Published: (2021-09-01)

<i>Pseudomonas aeruginosa</i>: Infections, Animal Modeling, and Therapeutics
by: Stephen J. Wood, et al.
Published: (2023-01-01)

Delafloxacin––A novel fluoroquinolone for the treatment of ciprofloxacin‐resistant Pseudomonas aeruginosa in patients with cystic fibrosis
by: Beverley Cherie Millar, et al.
Published: (2021-01-01)

The Impact of <i>Pseudomonas aeruginosa</i> Infection in Adult Cystic Fibrosis Patients—A Single Polish Centre Study
by: Sylwia Jarzynka, et al.
Published: (2023-12-01)

In vitro activity of cefiderocol against Pseudomonas aeruginosa isolated from cystic fibrosis patients
by: Marguerite L. Monogue, et al.
Published: (2023-12-01)

Effects of Mucin and DNA Concentrations in Airway Mucus on Pseudomonas aeruginosa Biofilm Recalcitrance
by: Kaitlyn R. Rouillard, et al.
Published: (2022-08-01)

Serratiopeptidase Affects the Physiology of <i>Pseudomonas aeruginosa</i> Isolates from Cystic Fibrosis Patients
by: Marco Artini, et al.
Published: (2022-10-01)

Giving Drugs a Second Chance: Antibacterial and Antibiofilm Effects of Ciclopirox and Ribavirin against Cystic Fibrosis <i>Pseudomonas aeruginosa</i> Strains
by: Giovanni Di Bonaventura, et al.
Published: (2022-04-01)

<i>Pseudomonas aeruginosa</i>: An Audacious Pathogen with an Adaptable Arsenal of Virulence Factors
by: Irene Jurado-Martín, et al.
Published: (2021-03-01)

Evaluation of a Novel Chromogenic Medium for the Detection of <i>Pseudomonas aeruginosa</i> in Respiratory Samples from Patients with Cystic Fibrosis
by: Thang V. Truong, et al.
Published: (2022-05-01)

Involvement of Acquired Tobramycin Resistance in the Shift to the Viable but Non-Culturable State in <i>Pseudomonas aeruginosa</i>
by: Gianmarco Mangiaterra, et al.
Published: (2023-07-01)

<i>Pseudomonas aeruginosa</i> Resistance to Bacteriophages and Its Prevention by Strategic Therapeutic Cocktail Formulation
by: Andrew Vaitekenas, et al.
Published: (2021-02-01)

Activity of Delafloxacin and Comparator Fluoroquinolones against Multidrug-Resistant <i>Pseudomonas aeruginosa</i> in an In Vitro Cystic Fibrosis Sputum Model
by: Vaughn D. Craddock, et al.
Published: (2023-06-01)

Effects of Levofloxacin, Aztreonam, and Colistin on Enzyme Synthesis by <i>P. aeruginosa</i> Isolated from Cystic Fibrosis Patients
by: Arianna Pani, et al.
Published: (2022-08-01)

Synergistic Activity of Repurposed Peptide Drug Glatiramer Acetate with Tobramycin against Cystic Fibrosis Pseudomonas aeruginosa
by: Ronan A. Murphy, et al.
Published: (2022-08-01)

Interplay between biofilm microenvironment and pathogenicity of Pseudomonas aeruginosa in cystic fibrosis lung chronic infection
by: Olivier Guillaume, et al.
Published: (2022-12-01)

Sub-Inhibitory Antibiotic Exposure and Virulence in <i>Pseudomonas aeruginosa</i>
by: Charlotte Nolan, et al.
Published: (2021-11-01)

Impact of <i>Pseudomonas aeruginosa</i> Infection on Patients with Chronic Inflammatory Airway Diseases
by: Marta Garcia-Clemente, et al.
Published: (2020-11-01)

Cystic Fibrosis Patients Infected With Epidemic Pseudomonas aeruginosa Strains Have Unique Microbial Communities
by: Nicole Acosta, et al.
Published: (2020-04-01)

Factoring in the Complexity of the Cystic Fibrosis Lung to Understand <i>Aspergillus fumigatus</i> and <i>Pseudomonas</i> <i>aeruginosa</i> Interactions
by: Emily Beswick, et al.
Published: (2020-08-01)

Analysis of the Phospholipid Profile of the Collection Strain PAO1 and Clinical Isolates of <i>Pseudomonas aeruginosa</i> in Relation to Their Attachment Capacity
by: Caroline Le Sénéchal, et al.
Published: (2021-04-01)

Antibacterial activity of iron oxide, iron nitride, and tobramycin conjugated nanoparticles against Pseudomonas aeruginosa biofilms
by: Leisha M. Armijo, et al.
Published: (2020-02-01)

Repurposing High-Throughput Screening Identifies Unconventional Drugs with Antibacterial and Antibiofilm Activities against Pseudomonas aeruginosa under Experimental Conditions Relevant to Cystic Fibrosis
by: Giovanni Di Bonaventura, et al.
Published: (2023-08-01)

The Iron-chelator, N,N’-bis (2-hydroxybenzyl) Ethylenediamine-N,N’-diacetic acid is an Effective Colistin Adjunct against Clinical Strains of Biofilm-Dwelling <i>Pseudomonas aeruginosa</i>
by: Karla Mettrick, et al.
Published: (2020-03-01)

Tackling Virulence of <em>Pseudomonas aeruginosa</em> by the Natural Furanone Sotolon
by: Mohammed F. Aldawsari, et al.
Published: (2021-07-01)

γδ T lymphocytes from cystic fibrosis patients and healthy donors are high TNF-α and IFN-γ-producers in response to <it>Pseudomonas aeruginosa</it>
by: Martínez Natalia, et al.
Published: (2003-09-01)

<i>Pseudomonas aeruginosa</i> PAO1 Is Attracted to Bovine Bile in a Novel, Cystic Fibrosis-Derived Bronchial Epithelial Cell Model
by: Shekooh Behroozian, et al.
Published: (2022-03-01)

The Impact of an Efflux Pump Inhibitor on the Activity of Free and Liposomal Antibiotics against <i>Pseudomonas aeruginosa</i>
by: Douweh Leyla Gbian, et al.
Published: (2021-04-01)

Interaction between Pseudomonas aeruginosa and Aspergillus fumigatus in cystic fibrosis
by: Jingming Zhao, et al.
Published: (2018-11-01)

Anti-Virulence Properties of <i>Coridothymus capitatus</i> Essential Oil against <i>Pseudomonas aeruginosa</i> Clinical Isolates from Cystic Fibrosis Patients
by: Gianluca Vrenna, et al.
Published: (2021-10-01)

A Novel Co-Culture Model Reveals Enhanced CFTR Rescue in Primary Cystic Fibrosis Airway Epithelial Cultures with Persistent <i>Pseudomonas aeruginosa</i> Infection
by: Deborah M. Cholon, et al.
Published: (2023-11-01)

<i>Scedosporium/Lomentospora</i> Species Induce the Production of Siderophores by <i>Pseudomonas aeruginosa</i> in a Cystic Fibrosis Mimic Environment
by: Thaís P. Mello, et al.
Published: (2023-04-01)

Bioenergetics of the polyphosphates accumulation in Pseudomonas aeruginosa via polyphosphate kinase activation by choline in a lung colonization model
by: Alejandro Rossi, et al.
Published: (2023-02-01)

The Impact of the Virulence of <i>Pseudomonas aeruginosa</i> Isolated from Dogs
by: Telma de Sousa, et al.
Published: (2023-05-01)

The role of 2,4-dihydroxyquinoline (DHQ) in Pseudomonas aeruginosa pathogenicity
by: Jordon D. Gruber, et al.
Published: (2016-01-01)

Interspecies interactions induce exploratory motility in Pseudomonas aeruginosa
by: Dominique H Limoli, et al.
Published: (2019-11-01)

Local and Systemic Alterations of the L-Arginine/Nitric Oxide Pathway in Sputum, Blood, and Urine of Pediatric Cystic Fibrosis Patients and Effects of Antibiotic Treatment
by: Beatrice Hanusch, et al.
Published: (2020-11-01)